The randomized, double-blind, placebo-controlled Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102 in healthy participants
Merck and mantro GmbH have established EdiMembre, Massachusetts, U.S.A., a Deep Tech spin-out in the alternative protein industry
Its lead product, Dasynoc, is awaiting FDA approval with a PDUFA date of October 7, 2025
Attorney General Ken Paxton sued pharmaceutical giant Eli Lilly for bribing and illegally inducing medical providers to prescribe its most profitable drugs
Glenmark USA is named in multiple antitrust and consumer protection lawsuits, including class actions, consolidated in the Eastern District of Pennsylvania, U.S
NJ Bio is currently executing a major new program for an existing innovator customer with multiple ADC candidates in their pipeline
AINU is set to accelerate its expansion footprint, enhance operational capabilities
FDA grants accelerated approval to zongertinib for HER2 TKD-Mutated Non-Squamous NSCLC
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
NorUDCA is the first?in?class treatment for Non?alcoholic Fatty Liver Disease (NAFLD) in India
Subscribe To Our Newsletter & Stay Updated
